Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And ...

Just when you had written off biotech stocks as boring, here comes the MIT Technology Review to name its “Three technologies that will shape biotech in 2026.” There’s no moonshot cure for cancer ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Biotech firms use AI in trials to target patients more ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon with biology through artificial-intelligence-powered drug development. The ...